Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Research & Development (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Research & Development for 8 consecutive years, with $17.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 9.58% year-over-year to $17.3 million, compared with a TTM value of $75.9 million through Sep 2025, up 0.92%, and an annual FY2024 reading of $81.6 million, up 13.37% over the prior year.
  • Research & Development was $17.3 million for Q3 2025 at X4 Pharmaceuticals, down from $18.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.1 million in Q1 2023 and bottomed at $12.1 million in Q1 2021.
  • Average Research & Development over 5 years is $16.8 million, with a median of $17.3 million recorded in 2025.
  • The sharpest move saw Research & Development skyrocketed 56.34% in 2022, then fell 19.68% in 2023.
  • Year by year, Research & Development stood at $12.2 million in 2021, then skyrocketed by 56.34% to $19.0 million in 2022, then dropped by 19.68% to $15.3 million in 2023, then soared by 42.1% to $21.7 million in 2024, then dropped by 20.11% to $17.3 million in 2025.
  • Business Quant data shows Research & Development for XFOR at $17.3 million in Q3 2025, $18.4 million in Q2 2025, and $18.5 million in Q1 2025.